Shots:
- Boehringer Ingelheim and Simcere have entered a license and collaboration agreement to develop SIM0709, a preclinical TL1A/IL-23p19 bispecific antibody, for the treatment of inflammatory bowel disease (IBD)
- As per the deal, Boehringer Ingelheim gains global rights to the asset excluding Greater China, while Simcere is eligible for an upfront payment, milestones up to €1.058B ($1.26B), and royalties on net sales outside Greater China territory
- SIM0709 is a long-acting humanized bispecific antibody that targets TL1A and IL-23, blocking two key IBD pathways and showing superior synergistic efficacy versus individual or combined monotherapies in preclinical studies
Ref: Boehringer Ingelheim | Image: BI and Simcere Pharmaceutical | Press Release
Related News: Janux Therapeutics and BMS Forge ~$850M Deal to Develop Therapies in Oncology
PharmaShots, your go-to media platform for customized news ranging across multiple indications. For more information, connect with us at connect@pharmashots.com
